MedTrace Logo

FT516 in Subjects With Advanced Hematologic Malignancies

NCT04023071 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-10-26

No results posted yet for this study

Summary

This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.

Conditions

Interventions

DRUG

FT516

Experimental Interventional Therapy

DRUG

Rituximab

Monoclonal Antibody

DRUG

Obinutuzumab

Monoclonal Antibody

DRUG

Cyclophosphamide

Conditioning agent

DRUG

Fludarabine

Conditioning agent

DRUG

IL-2

Biologic response modifier

DRUG

Bendamustine

Conditioning agent

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-04
Primary Completion
2023-10-23
Completion
2023-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04023071 on ClinicalTrials.gov